NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, ...
The Neurology Advisor Team spoke with Shilpa Reddy, MD, MMHC at AES 2025 in Atlanta, Georgia. Neurology Advisor: “Can you describe your work in neuromodulation?” ...
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...
Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study ...
Children referred to a first seizure clinic (FSC) see a neurologist epilepsy specialist within one week, according to a study ...
Xenon Pharmaceuticals Inc. ( XENE) Discusses Latest Phase III Updates for Azetukalner in Epilepsy and Commercial Launch Preparation December 10, 2025 10:00 AM EST ...
NeuroPace (NPCE) announced the presentation at the American Epilepsy Society meeting of preliminary 18-month safety and effectiveness results from ...
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eight abstracts, including four that are late-breaking, will be presented on Epidiolex® (cannabidiol) at the American Epilepsy Society (AES ...
Collection of eight posters include analyses of data from studies of diazepam nasal spray in treatment of episodes of ...
MedPage Today on MSN
For People With Seizures, It May Be Better to Be Old
ATLANTA -- In health matters it's not often that older people do better than their younger peers, but seizure disorders may be an example, suggested a cross-sectional study.
Midazolam for refractory status epilepticus reduces 30-day mortality and complications versus propofol, though long-term outcomes are similar.
Praxis Precision Medicines, Inc. soars after study success and pipeline wins. Explore key milestones, projections, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results